LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.

The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results have been accepted for presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The studies highlight the company's innovative research in T-cell engager-drug conjugates (TDCs) and dual-targeting ADCs, further validating the synergistic R&D strategy of its three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform).

The company recently released its annual results, reporting full-year revenue of approximately RMB 177 million, derived from an upfront and recent milestone payment received under a licensing agreement for LBL-047. Research and development costs increased significantly as the company advanced multiple pipeline assets.